Brian Clark Biotech Lecture: Simon Mølgaard

More than 10 million people worldwide live with Parkinson's disease, yet current treatments address symptoms rather than the underlying biology. Teitur Trophics was founded in 2020 as a spin-out from Aarhus University with a different ambition: to develop disease-modifying therapies that can slow or halt the progression of neurodegenerative diseases.
In this talk, Simon Mølgaard will share the story of building Teitur Trophics from a university discovery to a clinical-stage biotech. From the early science on SorCS receptors as novel drug targets, through BII funding and a €28M Series A, to the recent completion of a Phase I clinical trial of the company's lead candidate, TT-P34, in patients with Parkinson's disease. He will discuss what it takes to translate acade-mic research into a viable drug development program, how the company is structured and financed, and what kinds of scientific and operational profiles are needed at each stage of the journey.

Coffee and cake served from 13:45